Dear ALLSTAT members,
This one-day meeting has been organised for statisticians working in
clinical trials and wanting to learn about the statistical issues of health
economics.
Speakers from industry and academia will examine the problems facing
statisticians when analysing health economic and quality of life data.
Date: 26th September 2000.
Venue: Durham St Auditorium, Royal Society of Arts, Durham House St.
Entrance off the Strand, London WC2N 6EZ.
Registration Costs: PSI Members : £111.62; Non-members: £123.37 (Fee
includes lunch, refreshments and VAT.)
Agenda: David Taylor (South London & Maudsley NHS Trust) - Health
Economics in Decision Making
Pippa Anderson (4th Hurdle) - Differences between Health
Economic and Clinical Data: Implications for Trial Design and Analysis
Jeff Kirsch (SmithKline Beecham) - An Overview of Health Economics
in Clinical Trials
Andrew Briggs (University of Oxford) - Handling Missing Values in
Health Economics
Alan Stewart (AstraZeneca) - Modelling Health Economics Data
Ingela Wiklund (AstraZeneca) - Quality of Life Measurements
in Clinical Trials
Cindy Billingham (University of Birmingham) - Joint Analysis of
Quality of Life and Survival Data
Tracey Young (Brunel University) - Analysis of Cost Data
Nick Wells (Pfizer) - Statisticians in Health Economics
For more details, please visit the PSI website www.psiweb.org/meetings.htm
<http://www.psiweb.org/meetings.htm> , or contact:
Beverley Moore.
Tel: +44 (0)1625 511750
Fax: +44 (0)1625 267879
[log in to unmask] <mailto:[log in to unmask]>
PSI Executive Office
Resources for Business
South Park Road Macclesfield SK11 6SH, UK
Regards,
Sean McGuigan
Boehringer Ingelheim Ltd UK
Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
UK
Email: [log in to unmask]
<mailto:[log in to unmask]>
______________________________________________________________________________________
Important Notice
This message (including any attachments) is intended solely for the person(s) to whom it is addressed ("intended recipient"). It may contain copyright, confidential and/or privileged information, within the meaning of applicable law.
If you are not the intended recipient (or do not have authority to access the intended recipient's mail box) any disclosure, dissemination, distribution or copying of this e-mail or any attached documents is strictly prohibited.
If you are not the intended recipient, please contact the sender or Boehringer Ingelheim Limited (the "Company") as soon as possible and delete this e-mail and all attachments immediately.
Opinions or statements in this e-mail are not necessarily those of the Company. If you are in any doubt as to whether the opinions or statements in this e-mail are made on behalf of the Company, please contact the Public Relations Department of the Company.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|